EUCTR2010-019631-35-ES进行中（未招募）1 期
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT FROM A DECEASED DONOR
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients ? 18 years old
- •2. Patients with Stage V chronic kidney disease who will receive a kidney transplant from a deceased donor to whom they are sensitized
- •3. Patients must be able to understand the informed consent form and willing to comply with study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Has received treatment with eculizumab at any time prior to enrolling in this study
- •2. ABO incompatible with deceased donor
研究者
相似试验
进行中（未招募）
1 期
OPEN LABEL TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN DECEASED DONOR KIDNEY TRANSPLANT SENSITIZED RECIPIENTSAntibody mediated rejection after kidney transplantMedDRA version: 16.1Level: LLTClassification code 10064683Term: Antibody-mediated rejectionSystem Organ Class: 100000004870EUCTR2010-019631-35-SEAlexion Pharmaceuticals, Inc.80
进行中（未招募）
1 期
OPEN LABEL TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN DECEASED DONOR KIDNEY TRANSPLANT SENSITIZED RECIPIENTSEUCTR2010-019631-35-GBAlexion Pharmaceuticals, Inc.80
进行中（未招募）
1 期
AN OPEN-LABEL OF ECULIZUMAB IN THE PREVENTION OF AMR IN DECEASED DONOR KIDNEY TRANSPLANT SENSITIZED RECIPIENTSantibodymediated rejection after kidney trasplantMedDRA version: 14.1Level: LLTClassification code 10064683Term: Antibody-mediated rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2010-019631-35-ITALEXION PHARMACEUTICALS40
进行中（未招募）
不适用
Chemotherapy with cabazitaxel in advanced prostate cancerEUCTR2011-003156-39-FITampere University Hospital60
进行中（未招募）
1 期
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants =10 Years of Ageprevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup BMedDRA version: 20.0Level: LLTClassification code 10027276Term: Meningococcal meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002588-24-CZPfizer Inc.50